Basel, Switzerland – BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focused on developing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced that its management will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held from September 14 to 16, 2026, in New York City.
The company's Chief Financial Officer, Hernan Levett, will deliver the presentation on September 16, 2026, from 12:30 PM to 1:00 PM ET at the Kennedy II room on the 4th floor of the Lotte New York Palace. Additionally, a pre-recorded on-demand presentation by Dr. Marc Gitzinger, Chief Executive Officer, will be available starting September 11, 2026, at 7:00 AM ET, with replays accessible for 90 days via the H.C. Wainwright platform or the BioVersys website's investor section.
This participation underscores BioVersys's commitment to addressing the escalating global health crisis of antimicrobial resistance (AMR). The company's pipeline includes BV100, a Phase 3 candidate targeting nosocomial infections caused by Acinetobacter baumannii, and alpibectir, a Phase 2 tuberculosis treatment developed in collaboration with GlaxoSmithKline (GSK) and a consortium led by the University of Lille, France. These programs highlight BioVersys's focus on infections where multidrug resistance poses significant treatment challenges.
The announcement comes at a time when the World Health Organization has repeatedly emphasized the urgent need for new antibiotics. The rise of MDR bacteria threatens to undermine modern medicine, making infections that were once easily treatable potentially deadly. BioVersys's approach leverages two internal technology platforms: TRIC and Ansamycin Chemistry. These platforms aim to overcome resistance mechanisms, block virulence production, and directly affect the pathogenesis of harmful bacteria, potentially offering new treatment options in antimicrobial and microbiome fields.
For investors and industry observers, the presentation at this major conference provides an opportunity to gain insights into BioVersys's strategic direction and the progress of its clinical programs. The company's participation also reflects the growing interest in innovative solutions to combat AMR, a market projected to reach significant value as healthcare systems worldwide prioritize the development of new antibiotics.
BioVersys's management will be available for one-on-one meetings with registered attendees during the conference, facilitating deeper discussions about the company's potential and the broader implications of its work. The company's presence at such a prestigious event signals its commitment to engaging with the investment community and advancing its mission to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders.
